Argenx price target raised to $700 from $660 at Truist

Truist raised the firm’s price target on Argenx (ARGX) to $700 from $660 and keeps a Buy rating on the shares. The company’s Q4 revenue guidance was materially ahead of consensus estimates, while its 2025 R&D and SG&A guidance of $2.5BN against growing topline puts Argenx on a continued path to profitability, the analyst tells investors in a research note. At current trajectory, Argenx remains well poised to not only achieve but likely exceed “Vision 2030”, and the stock is seen as one of Truist’s “favorite names for 2025”, the firm adds.